Table I.
Characteristics of 69 older adults with current major depressive episode, at baseline, overall and by 5HTTLPR and HRT1B expression status.
| Total sample (n = 69) | 5HTTLPR high expressing (n = 45) | 5HTTLPR low expressing (n = 22) | P value | HTR1B high expressing (n = 45) | HTR1B low expressing (n = 21) | P value | |
|---|---|---|---|---|---|---|---|
| Age, mean (SD) | 69.0 (7.1) | 69.0 (6.9) | 68.4 (7.3) | 0.76 | 69.2 (6.8) | 68.3 (7.5) | 0.61 |
| Gender, n (%Female) | 43.0 (62.3) | 27.0 (60.0) | 14.0 (63.6) | 0.77 | 29.0 (64.4) | 12.0 (57.1) | 0.57 |
| Baseline MADRS, mean (SD) | 26.8 (5.8) | 26.8 (5.7) | 25.6 (4.9) | 0.38 | 26.2 (5.2) | 26.9 (6.2) | 0.64 |
| MADRS score change, mean (SD) | −10.7 (9.7) | −9.9 (10.3) | −11.2 (7.2) | 0.58 | −10.8 (8.2) | −9.7 (11.8) | 0.70 |
| RBANS, mean (SD) | 96.2 (17.4) | 97.6 (16.3) | 94.8 (19.1) | 0.53 | 96.4 (15.9) | 97.8 (20.7) | 0.78 |
| Baseline BMI, mean (SD) | 30.4 (7.1) | 30.6 (7.8) | 30.0 (5.5) | 0.74 | 30.4 (6.7) | 29.7 (7.4) | 0.74 |
| BMI score change, mean (SD) | −0.86 (3.5) | −0.9 (4.1) | −0.8 (1.9) | 0.85 | −0.4 (1.2) | −1.6 (5.7) | 0.39 |
| Pre-study SSRIs, n (%) | 28.0 (40.6) | 20.0 (44.4) | 8.0 (36.4) | 0.53 | 19.0 (42.2) | 8.0 (38.1) | 0.75 |
| Final Venla dose mg, mean (SD) | 252.2 (64.0) | 257.5 (61.7) | 240.3 (74.1) | 0.31 | 253.3 (66.0) | 246.4 (63.4) | 0.69 |
| Final Norvenal conc ng/ml, mean (SD) | 320.1 (157.9) | 326.3 (159.4) | 310.1 (164.8) | 0.70 | 324.6 (167.1) | 310.6 (151.3) | 0.75 |
| Final Venla conc ng/ml, mean (SD) | 193.7 (177.8) | 214.0 (196.8) | 156.1 (135.1) | 0.22 | 209.9 (189.3) | 161.8 (162.1) | 0.32 |
| Any bone meds, n (%) | 23.0 (33.3) | 17.0 (37.8) | 5.0 (22.7) | 0.22 | 16.0 (35.6) | 5.0 (23.8) | 0.34 |
| Bisphosphonate or Estrogen, n (%) | 8.0 (11.6) | 7.0 (15.6) | 1.0 (4.6) | 0.26 | 7.0 (15.6) | 1.0 (4.8) | 0.21 |
MADRS, Montgomery–Asberg Depression Rating Scale; RBANS, Repeatable Battery for the Assessment of Neuropsychological Status; BMI, body mass index; SSRIs, selective serotonin reuptake inhibitors; Venla, venlafaxine; Norvenla, norvenlafaxine; Any bone meds: includes bisphosphonates, calcium, vitamin D and estrogen.